หน้าแรก
ค้นหา
Steven Pipe: Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
No description available
แสดงข้อมูลเพิ่มเติม 1
Steven Pipe: Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
Dr. Steven Pipe on hemophilia B’s first gene therapy, HEMGENIX
An update on HOPE B Gene Therapy Trial from Stevne Pipe, MD
Steve Pipe discusses the latest on Etranacogene Dezaparvovec (AAV5-Padua hFIX variant)
Positive Follow-Up Results in Patients With Hemophilia B Given Gene Therapy (Hemgenix)
Final Analysis from the Pivotal Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec
Phase 3 HOPE-B Trial of etranacogene dezaparvovec in Severe/Moderately Severe Hemophilia B
Dr. Steven W. Pipe discusses the latest on BAY 2599023
How the Gene Therapy for Hemophilia B Got FDA Approval (the HOPE-B trial)
Long-term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption
$3.5 Million Gene Therapy for Hemophilia B Now Available for Patients
Steve Pipe discusses Phase 3 HOPE-B Gene Therapy Trial
Steven Pipe, MD: Changing the Delivery of Bleeding Prevention for Hemophilia Patients
Data from Phase 3 Gene Therapy Trial in Hemophilia B Patients Very Encouraging
Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B
HOPE-B: etranacogene dezaparvovec in adult hemophilia B
Current AAV Hemophilia B Gene Therapy Trials
Etranacogene Dezaparvovec (AAV5-Padua hFIX variant): Two Year Data From a Phase 2b Trial
Gene therapy as a future treatment for hemophilia
Safety of Gene Therapy for Hemophilia: Now and in the Future
